All In Biotech

Drug Trial Radar · NCT05914116

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

862

Planned (sponsor's estimate)

Start

Aug 17, 2023

Primary completion

Dec 2027

Study completion May 2028

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • DB-1311Drug

    Administered I.V.(intravenous infusion)

  • Lopinavir and Ritonavir TabletsDrug

    Lopinavir and Ritonavir Tablets

  • itraconazoleDrug

    itraconazole

  • EnzalutamideDrug

    oral administration

  • AbirateroneDrug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Percentage of participants in Part 1 with DLTsTime frame: up to 21 days after Cycle 1 Day 1
  2. Phase 1& Phase 2a: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
  3. Phase 1& Phase 2a: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
  4. Phase 1 & Phase 2a: vital sign measurementsTime frame: Up to follow-up period, approximately 1 year post-treatment
  5. Phase 1& Phase 2a: clinical safety laboratory parametersTime frame: Up to follow-up period, approximately 1 year post-treatment
  6. Phase 1& Phase 2a: Electrocardiogram (ECG) parametersTime frame: Up to follow-up period, approximately 1 year post-treatment
  7. Phase 1& Phase 2a: Eastern Cooperative Oncology Group (ECOG) performance status (PS)Time frame: Up to follow-up period, approximately 1 year post-treatment
  8. Phase 1& Phase 2a: left ventricular ejection fraction (LEVF)Time frame: Up to follow-up period, approximately 1 year post-treatment
  9. Phase 1: Maximum Tolerated Dose (MTD) of DB-1311/BNT324Time frame: Up to the completion of Part 1 (assessed up to 12 months)
  10. Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1311/BNT324Time frame: Up to the completion of Part 1 (assessed up to 12 months)
  11. Phase 2a: Objective Response Rate (ORR) as determined by investigatorTime frame: Up to follow-up period, approximately 1 year post-treatment

Locations

107 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site 111

    Tucson, Arizona · Recruiting

  • Research Site 125

    Los Angeles, California · Recruiting

  • Research Site 133

    Los Angeles, California · Recruiting

  • Research Site 103

    Los Angeles, California · Recruiting

  • Research Site 128

    Santa Monica, California · Recruiting

  • Research Site 118

    Celebration, Florida · Recruiting

  • Research Site 127

    Margate, Florida · Recruiting

  • Research Site 137

    Orlando, Florida · Recruiting

  • Research Site 101

    Plantation, Florida · Recruiting

  • Research Site 109

    Tamarac, Florida · Recruiting

  • Research Site 114

    Atlanta, Georgia · Recruiting

  • Research Site 139

    Atlanta, Georgia · Recruiting

  • Research Site 115

    Louisville, Kentucky · Recruiting

  • Research Site 129

    Detroit, Michigan · Recruiting

  • Research Site 121

    Saint Paul, Minnesota · Recruiting

  • Research Site 110

    Las Vegas, Nevada · Recruiting

  • Research Site 107

    New York, New York · Recruiting

  • Research Site 138

    Canton, Ohio · Recruiting

  • Research Site 113

    Cincinnati, Ohio · Recruiting

  • Research Site 131

    Dayton, Ohio · Recruiting

  • Research Site 123

    Charleston, South Carolina · Recruiting

  • Research Site 108

    Greenville, South Carolina · Recruiting

  • Research Site 136

    Nashville, Tennessee · Recruiting

  • Research Site 135

    Austin, Texas · Recruiting

  • Research Site 120

    Dallas, Texas · Recruiting

  • Research Site 102

    Fairfax, Virginia · Recruiting

  • Research Site 112

    Fairfax, Virginia · Recruiting

  • Research Site 105

    Spokane, Washington · Recruiting

  • Research Site 208

    Blacktown, New South Wales, Australia · Recruiting

  • Research Site 215

    Camperdown, New South Wales, Australia · Recruiting

  • Research Site 212

    Concord, New South Wales, Australia · Recruiting

  • Research Site 217

    New Lambton Heights, New South Wales, Australia · Recruiting

  • Research Site 201

    Sydney, New South Wales, Australia · Recruiting

  • Research Site 205

    Sydney, New South Wales, Australia · Recruiting

  • Research Site 206

    Sydney, New South Wales, Australia · Recruiting

  • Research Site 216

    Waratah, New South Wales, Australia · Recruiting

  • Research Site 209

    Birtinya, Queensland, Australia · Recruiting

  • Research Site 203

    Brisbane, Queensland, Australia · Recruiting

  • Research Site 210

    Gold Coast, Queensland, Australia · Recruiting

  • Research Site 202

    Nedlands, Western Australia, Australia · Recruiting

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.